Know Labs Participating in Second Annual Bernstein CGM Disruptors Conference

Rhea-AI Summary

Know Labs, Inc. (NYSE AMERICAN: KNW) will present at the Bernstein CGM Disruptors Conference on November 18, 2022. The company will update its Bio-RFID technology, aimed at non-invasive glucose monitoring. Bio-RFID uses radio-frequency spectroscopy to detect analytes in the bloodstream, with the first application being a glucose monitor that provides real-time blood glucose levels. This product requires FDA approval before market introduction. Know Labs focuses on integrating its technology into wearable devices for better health monitoring.

Positive

• Know Labs to present at the Bernstein CGM Disruptors Conference, increasing visibility.
• Updates on Bio-RFID technology show progress in non-invasive glucose monitoring.

Negative

• The glucose monitoring product still requires FDA approval, delaying market entry.

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (NYSE AMERICAN: KNW), an emerging leader in non-invasive medical diagnostic technology, will present at the second annual Bernstein CGM Disruptors Conference www.bernsteinresearch.com on Friday, Nov. 18, 2022. At the virtual event, attendees from across the globe will gather to discuss new developments in continuous glucose monitoring technology.

During the conference, Know Labs will provide an update on its innovative Bio-RFID technology and will share progress on bringing its non-invasive glucose monitoring medical devices to market. Bio-RFID is the patented, proprietary non-invasive medical diagnostic technology platform developed by Know Labs. Bio-RFID uses radio-frequency spectroscopy to detect and measure analytes, such as glucose, in the bloodstream. For more information on Know Labs and Bio-RFID, visit www.knowlabs.co.

About Know Labs, Inc.

Know Labs, Inc. is a development stage public company whose shares trade on the NYSE American exchange under the stock symbol “KNW.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a non-invasive glucose monitor. It will provide the user with real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration approval prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2021, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221107005203/en/

Know Labs, Inc. Contact:

Jordyn Hujar

jordyn@knowlabs.co

Ph. (206) 629-6414

Linhart PR for Know Labs Media Inquiries:

Mallory West

mwest@linhartpr.com

Ph. (317) 439-3173

Source: Know Labs, Inc.

FAQ

What is Know Labs, Inc. doing at the Bernstein Conference on November 18, 2022?

Know Labs, Inc. will present updates on its Bio-RFID technology and progress in non-invasive glucose monitoring.

What technology is Know Labs focusing on for glucose monitoring?

Know Labs is focusing on its proprietary Bio-RFID technology, which uses radio-frequency spectroscopy.

What is the stock symbol for Know Labs, Inc.?

The stock symbol for Know Labs, Inc. is KNW.

Does the Bio-RFID technology require any approvals before market launch?

Yes, the Bio-RFID glucose monitoring product requires FDA approval before it can be introduced to the market.